XBIT News and Press, XBiotech Inc. From 10/23/19

Enrollment is underway in a Phase 2 clinical trial evaluating XBiotech's ( XBIT -0.3% ) bermekimab in patients with hidradenitis suppurativa, a condition characterized by small painful lumps under the skin, typically in area where skin rubs together (e.g., armpits, groin, buttocks, br...

AUSTIN, Texas, Oct. 23, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). ...

Noteworthy events during the week of October 6 - 12 for healthcare investors. More news on: Alnylam Pharmaceuticals, Inc., Summit Therapeutics, XBiotech Inc., Healthcare stocks news, , Read more ...

AUSTIN, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced the first patient was enrolled in a clinical study evaluating bermekimab therapy in adults with systemic sclerosis (SSc), otherwise known as scleroderma, a devastating inflammatory syndrome characterized by c...

AUSTIN, Texas, Sept. 27, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that Dr. Alice Gottlieb will be presenting clinical findings for bermekimab in the treatment of atopic dermatitis (AD) at the European Academy of Dermatology and Venereology (EADV) Congress being held ...

The Canadian Patent Office has granted XBiotech (NASDAQ: XBIT ) a Patent Number 56003542-6CA covering the use of bermekimab in the treatment of inflammatory skin diseases. More news on: XBiotech Inc., Healthcare stocks news, Read more ...

AUSTIN, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) covering the use of bermekimab in the treatment of inflammatory skin diseases. The patent describes studies ...

Upcoming randomized, double-blind, placebo controlled Phase 2 study follows recent successful open label study in Atopic Dermatitis (AD) AUSTIN, Texas, July 11, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announces that Seth Forman, M.D., will Chair the Company’s upcoming random...

AUSTIN, Texas, July 10, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that Peter Libby, M.D., has been appointed to the Company’s Corporate Board of Directors.  Dr. Libby has played a pioneering role in discovering how inflammation leads to cardiovascular...

AUSTIN, Texas, July 09, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the Medical Research Council (MRC), part of UK Research and Innovation, has awarded funding to study bermekimab therapy in a Phase 2 multi-center study in advanced cancers. The MRC will provide fun...